期刊文献+

预防性使用粒细胞集落刺激因子对乳腺癌辅助化疗所致中性粒细胞减少的影响 被引量:5

Effect of granulocyte colony-stimulating factor as prophylaxis on adjuvant chemotherapy-induced neutropenia in breast cancer patients receiving chemotherapy with epirubicin and cyciophosphamide
收藏 分享 导出
摘要 目的:比较聚乙二醇化重组人粒细胞集落刺激因子(pegylated recombinant human granulocyte colony-stimulating factor,PEG-rh G-CSF)和重组人粒细胞集落刺激因子(recombinant human granulocyte colony-stimulating factor,rh G-CSF)防治EC方案(表柔比星联合环磷酰胺)辅助化疗乳腺癌患者中性粒细胞减少的疗效和安全性。方法:选择2013年10月—2015年3月接受EC方案辅助化疗的乳腺癌患者135例,分为预防组(54例)和非预防组(81例);预防组又分为PEGrh G-CSF组(19例)和rh G-CSF组(35例)。PEG-rh G-CSF组化疗结束后48 h给予PEG-rh G-CSF 3.0 mg皮下注射1次;rh G-CSF组化疗结束后48 h给予rh-G-CSF 5μg·kg^-1·d^-1皮下注射1次,连续注射3~5 d。结果:预防组与非预防组的3或4度中性粒细胞减少发生率和中性粒细胞减少性发热发生率的差异均有统计学意义(P值均〈0.05)。PEG-rh GCSF组与rh G-CSF组的3或4度中性粒细胞减少发生率差异有统计学意义(P〈0.05)。PEG-rh G-CSF组与rh G-CSF组的中性粒细胞减少性发热、骨关节疼痛、乏力、发热和注射部位疼痛发生率的差异均无统计学意义(P值均〉0.05)。结论:接受EC方案辅助化疗的乳腺癌患者应预防性使用粒细胞集落刺激因子类药物。PEG-rh G-CSF可有效预防中性粒细胞减少,值得在临床上进行推广和应用。 Objective: To compare the efficacy of pegylated recombinant human granulocyte colonystimulating factor (PEG-rhG-CSF) versus recombinant human granulocyte colony-stimulating factor (rhG-CSF) as prophylaxis of adjuvant chemotherapy (EC regimen: epirubicin combined with cyclophosphamide)-induced neutropenia in patients with breast cancer, and examine the safety.Methods: A total of 135 breast cancer patients regimen between October 2013 and March 2015 receiving adjuvant chemotherapy with EC were divided into prophylactic group (n = 54) and non-prophylactic group (n = 81). The prophylactic group was further divided into PEG-rhG-CSF group (n = 19) and rhG-CSF group (n = 35). The PEG-rhG-CSF group was defined as being given PEG-rhG-CSF of single dose (3 mg) subcutaneously 48 hours after the end of the chemotherapy; the rhG-CSF group was defined as being given rhG-CSF 5μg· kg^-1 · d^- 1 subcutaneously 48 hours after the end of the chemotherapy and for 3-5 days.Results: There were significant differences in the incidence rates of grade 3/4 neutropenia and febrile neutropenia (FN) between the prophylactic group and non-prophylactic group (both P 〈 0.05). There were no significant differences in incidence rates of FN, bone joint pain, fatigue, fever and injection-site pain between PEG-rhG-CSF group and rhG-CSF group (all P 〉 0.05).Conclusion: Breast cancer patients receiving adjuvant chemotherapy with EC regimen should be prophylactically treated with G-CSF. PEG-rhG-CSF, which can prevent neutropenia effectively, is worth to be widely applied in clinical practice.
作者 王环 李惠平 宋国红 邸立军 邵彬 严颖 姜晗昉 梁旭 宛凤玲 张如艳 冉然 刘笑然 王晶 孔维垚 WANG Huan, LI Huiping, SONG Guohong, DI Lijun, SHAO Bin, YAN Ying, JIANG Hanfang, LIANG Xu, WAN Fengling, ZHANG Ruyan, RAN Ran, LIU Xiaoran, WANG Jing, KONG Weyao (Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China)
出处 《肿瘤》 CAS CSCD 北大核心 2016年第11期1239-1245,共7页 Tumor
关键词 乳腺肿瘤 辅助化疗 聚乙二醇化重组人粒细胞集落刺激因子 重组人粒细胞集落刺激因子 中性粒细胞减少 Breast neoplasms Adjuvant chemotherapy Pegylated recombinant human granulocyte colony-stimulating factor Recombinant human granulocyte colony-stimulating factor Neutropenia
作者简介 Correspondence to:LI Huiping(李惠平),E—mail:huipingii2012@hotmail.com
  • 相关文献

参考文献7

二级参考文献68

共引文献457

同被引文献42

引证文献5

二级引证文献5

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈